385 related articles for article (PubMed ID: 30778772)
1. The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer.
Perdrizet K; Leighl NB
Curr Treat Options Oncol; 2019 Feb; 20(3):21. PubMed ID: 30778772
[TBL] [Abstract][Full Text] [Related]
2. Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.
Melosky B; Juergens R; Hirsh V; McLeod D; Leighl N; Tsao MS; Card PB; Chu Q
Oncologist; 2020 Jan; 25(1):64-77. PubMed ID: 31138727
[TBL] [Abstract][Full Text] [Related]
3. Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials.
Connock M; Armoiry X; Tsertsvadze A; Melendez-Torres GJ; Royle P; Andronis L; Clarke A
BMC Cancer; 2019 Apr; 19(1):392. PubMed ID: 31023244
[TBL] [Abstract][Full Text] [Related]
4. Real-world treatment efficacy of anti-programmed death-1 combined with anti-angiogenesis therapy in non-small cell lung cancer patients.
Qiu L; Zhao X; Shi W; Sun S; Zhang G; Sun Q; Meng J; Xiong Q; Qin B; Jiao S
Medicine (Baltimore); 2020 Jun; 99(24):e20545. PubMed ID: 32541476
[TBL] [Abstract][Full Text] [Related]
5. The role of anti-angiogenesis in non-small-cell lung cancer: an update.
Villaruz LC; Socinski MA
Curr Oncol Rep; 2015 Jun; 17(6):26. PubMed ID: 25947099
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of immunotherapy combined with single-agent chemotherapy as second- or later-line therapy for metastatic non-small cell lung cancer.
Chen D; Li L; Wang M; Hu X; Jiang J; Li W; Yang L; Fan M; Shi Y; Lv F; Liu Y
Front Immunol; 2023; 14():1086479. PubMed ID: 37795095
[TBL] [Abstract][Full Text] [Related]
7. Clinical status and perspective on the application of immunotherapy combined with chemotherapy in advanced non-small cell lung cancer: a review.
Wang T; Zhang L; Cheng Y
Chin Clin Oncol; 2024 Apr; 13(2):26. PubMed ID: 38600808
[TBL] [Abstract][Full Text] [Related]
8. Current state of immunotherapy for non-small cell lung cancer.
Malhotra J; Jabbour SK; Aisner J
Transl Lung Cancer Res; 2017 Apr; 6(2):196-211. PubMed ID: 28529902
[TBL] [Abstract][Full Text] [Related]
9. The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials.
Saeed A; Park R; Sun W
J Hematol Oncol; 2021 Jan; 14(1):13. PubMed ID: 33436042
[TBL] [Abstract][Full Text] [Related]
10. Combination strategies of immunotherapy in non-small cell lung cancer: facts and challenges.
Li CL; Song Y
Chin Med J (Engl); 2021 Aug; 134(16):1908-1919. PubMed ID: 34343148
[TBL] [Abstract][Full Text] [Related]
11. When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?
Mhanna L; Guibert N; Milia J; Mazieres J
Curr Treat Options Oncol; 2019 Jun; 20(7):60. PubMed ID: 31172347
[TBL] [Abstract][Full Text] [Related]
12. Comparison of different maintenance regimens following first-line immunochemotherapy for advanced non-small cell lung cancer.
Li F; Wang H; Xiang Y; Li R; Li C; Zhong R; Li J; Xiong S; Liang L; He J; Liang W
Transl Lung Cancer Res; 2023 Dec; 12(12):2381-2391. PubMed ID: 38205212
[TBL] [Abstract][Full Text] [Related]
13. Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Ramjiawan RR; Griffioen AW; Duda DG
Angiogenesis; 2017 May; 20(2):185-204. PubMed ID: 28361267
[TBL] [Abstract][Full Text] [Related]
14. Perioperative Immunotherapy in Non-Small Cell Lung Cancer.
O'Brien J; Bodor JN
Curr Treat Options Oncol; 2023 Dec; 24(12):1790-1801. PubMed ID: 38091187
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapies in non-small cell lung cancer.
Kyle F; Spicer J
Cancer Imaging; 2008 Nov; 8(1):199-205. PubMed ID: 19028612
[TBL] [Abstract][Full Text] [Related]
16. Toxicity with small molecule and immunotherapy combinations in non-small cell lung cancer.
Adderley H; Blackhall FH; Lindsay CR
Cancer Immunol Immunother; 2021 Mar; 70(3):589-595. PubMed ID: 32915318
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapeutic agents for colorectal cancer.
Chee CE; Sinicrope FA
Gastroenterol Clin North Am; 2010 Sep; 39(3):601-13. PubMed ID: 20951919
[TBL] [Abstract][Full Text] [Related]
18. Advanced Non-Small-Cell Lung Cancer in Elderly Patients: Patient Features and Therapeutic Management.
Takayuki N; Keiko T; Junji U; Yoshiko K; Nobuyo T; Tadaaki Y; Koichi T
Biomed Res Int; 2018; 2018():8202971. PubMed ID: 29854794
[TBL] [Abstract][Full Text] [Related]
19. IPSOS trial: A "game changer" redefining first-line immunotherapy in platinum-ineligible NSCLC.
García-Pardo M; Mezquita L
Med; 2023 Nov; 4(11):745-748. PubMed ID: 37951206
[TBL] [Abstract][Full Text] [Related]
20. Current views on molecularly targeted therapy for lung cancer - a review of literature from the last five years.
Rybarczyk-Kasiuchnicz A; Ramlau R
Kardiochir Torakochirurgia Pol; 2018 Jun; 15(2):119-124. PubMed ID: 30069193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
